OncoMatch

OncoMatch/Clinical Trials/NCT06048133

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Is NCT06048133 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Gemcitabine and Cisplatin for biliary tract carcinoma.

Phase 2RecruitingNataliya UbohaNCT06048133Data as of May 2026

Treatment: Gemcitabine · Cisplatin · Zimberelimab · Quemliclustat — This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for early safety signals of the proposed drug combination. Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects. Participants will receive 4 cycles of combination therapy as described. After 4 cycles (\~6 months), cisplatin will be discontinued, while gemcitabine, zimberelimab (AB122), and quemliclustat (AB680) will be continued. Subjects will be treated until disease progression or development of intolerable toxicities. In total, there will be up to 39 participants on the study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Disease stage

Required: Stage III, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: gemcitabine (gemcitabine)

Prior therapy with gemcitabine ... for the treatment of BTC

Cannot have received: platinum-based chemotherapy (cisplatin)

Prior therapy with ... cisplatin ... for the treatment of BTC

Cannot have received: immune checkpoint inhibitor

Prior therapy with ... any immune checkpoint inhibitors for the treatment of BTC

Lab requirements

Blood counts

Adequate organ function as detailed in the protocol

Kidney function

Adequate organ function as detailed in the protocol

Liver function

Adequate organ function as detailed in the protocol

Adequate organ function as detailed in the protocol

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
  • University of Michigan Health System · Ann Arbor, Michigan
  • Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
  • University of Wisconsin · Madison, Wisconsin

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify